LadRx Corporation
11726 San Vicente Boulevard
Suite 650
Los Angeles
California
90049
United States
Tel: 310-826-5648
Fax: 310-826-6139
Website: http://www.cytrx.com/
518 articles about LadRx Corporation
-
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
1/3/2022
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022.
-
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
12/21/2021
CytRx Corporation today highlighted ImmunityBio, Inc.'s (NASDAQ: IBRX) ("ImmunityBio") recent clinical developments in the study of aldoxorubicin to treat various cancers.
-
CytRx Comments on Quarterly Results and Recent Strategic Initiatives - Nov 12, 2021
11/12/2021
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, commented on its results for the quarter ended September 30, 2021.
-
CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
11/9/2021
CytRx Corporation announced that Centurion BioPharma Corporation, a private wholly owned subsidiary that focuses on advancing the Company’s proprietary, albumin binding ultra-high potency LADR™ oncology drug candidates, has been invited to present plans for a world-class cancer treatment center in Las Vegas, Nevada.
-
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C
11/2/2021
CytRx Corporation today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") encouraging regulatory update following its recently held Type A meeting with the U.S. Food and Drug Administration ("FDA") on arimoclomol
-
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
10/14/2021
CytRx Corporation today highlighted ImmunityBio, Inc.'s (NASDAQ: IBRX) ("ImmunityBio") announced completion of enrollment in its Phase 2 trial studying a combination immunotherapy (Nant Cancer Vaccine)
-
CytRx to Present at Upcoming Virtual LD Micro Conference
10/5/2021
CytRx Corporation today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present at the Virtual LD Micro Main Event XIV, which is being held from October 12-14, 2021.
-
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
CytRx to Present at the H.C. Wainwright 23 rd Annual Global Investment Conference
-
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
8/24/2021
CytRx Corporation today highlighted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") published the results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD).
-
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
8/12/2021
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, commented on its results for the second quarter ended June 30, 2021.
-
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
7/29/2021
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine (U.S. Patent 11,071,774).
-
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
7/29/2021
CytRx Corporation announced that based on results from its 2021 Annual Meeting of Stockholders, both of the Company’s Class III director candidates – Joel K. Caldwell, CPA and Jennifer K. Simpson, Ph.D. – have been elected to the Board of Directors.
-
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
7/16/2021
CytRx Corporation today announced the closing of its previously announced sale of its securities pursuant to a securities purchase agreement (the “Purchase Agreement”) to a single healthcare-focused institutional investor (the “Investor”) for aggregate gross proceeds of approximately $10 million.
-
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
7/13/2021
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million.
-
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
6/30/2021
CytRx Corporation recently announced 24-month interim results of an open-label extension (OLE) trial of arimoclomol for the treatment of Niemann-Pick disease type C (NPC).
-
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
6/18/2021
CytRx Corporation (OTCQB: CYTR) ("CytRx"), today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (“NPC”
-
CytRx to Present at Upcoming Investor Conferences
6/2/2021
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present in the following upcoming conferences: LD Micro Invitational XI Conference: June 8-10, 2021
-
CytRx Comments on Quarterly Results and Year-to-Date Progress
5/13/2021
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the first quarter
-
CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
5/7/2021
CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that the ORARIALS-01 pivotal trial for arimoclomol in Amyotrophic Lateral Sclerosis (“ALS”) did not meet primary and secondary endpoints to show benefit in people living with the disease.
-
CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis
4/1/2021
CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (“IBM”) did not meet its primary and secondary endpoints.